State of New Jersey Common Pension Fund D Lowers Holdings in Vaxcyte, Inc. $PCVX

State of New Jersey Common Pension Fund D decreased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 40.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 39,880 shares of the company’s stock after selling 26,778 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Vaxcyte were worth $1,840,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Allworth Financial LP lifted its stake in shares of Vaxcyte by 148.9% in the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after purchasing an additional 731 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Vaxcyte in the 3rd quarter valued at about $45,000. CIBC Private Wealth Group LLC raised its holdings in Vaxcyte by 22,500.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after buying an additional 1,350 shares during the period. FNY Investment Advisers LLC acquired a new position in Vaxcyte in the third quarter valued at about $72,000. Finally, Danske Bank A S acquired a new position in Vaxcyte in the third quarter valued at about $76,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Stock Performance

Shares of PCVX opened at $53.01 on Monday. The stock has a 50-day simple moving average of $58.41 and a 200-day simple moving average of $51.83. Vaxcyte, Inc. has a 1 year low of $28.64 and a 1 year high of $65.00. The stock has a market capitalization of $7.65 billion, a PE ratio of -7.70 and a beta of 1.30.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter in the previous year, the business earned ($1.04) EPS. Analysts predict that Vaxcyte, Inc. will post -7.46 EPS for the current year.

Analyst Ratings Changes

PCVX has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. BTIG Research upped their price objective on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Guggenheim reaffirmed a “buy” rating and set a $116.00 price objective on shares of Vaxcyte in a research report on Monday, February 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Finally, Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

Insider Buying and Selling at Vaxcyte

In related news, CAO Elvia Cowan sold 3,000 shares of the stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total value of $180,000.00. Following the transaction, the chief accounting officer owned 28,975 shares of the company’s stock, valued at $1,738,500. This represents a 9.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 7,395 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $58.88, for a total value of $435,417.60. Following the completion of the sale, the chief operating officer owned 166,818 shares in the company, valued at approximately $9,822,243.84. This represents a 4.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 17,037 shares of company stock worth $994,899 in the last three months. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.